Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Receivables - Other data on file, last reported at $1.0 million in Q1 2026.

• On a quarterly basis, Receivables - Other fell 58.33% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $1.0 million, a 58.33% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 50.0% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.0 million, roughly flat from $1.0 million in the prior quarter.
• Over the last five years, Receivables - Other for RARE reached as high as $12.7 million in Q1 2023 and fell as low as $200000.0 in Q1 2024.
• Historically, Receivables - Other has averaged $2.7 million across 5 years, with a median of $2.1 million in 2025.
• Across the five-year window, Receivables - Other tumbled 98.43% in 2024 and soared 1100.0% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $6.4 million in 2022, then tumbled by 82.81% to $1.1 million in 2023, then soared by 81.82% to $2.0 million in 2024, then slumped by 50.0% to $1.0 million in 2025, then changed by 0.0% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.0 million in Q1 2026, $1.0 million in Q4 2025, and $2.1 million in Q3 2025.